NASDAQ · Biotechnology

PVLA (PVLA) Stock

$140.25 -1.82% NASDAQ: PVLA Healthcare

Valuation

MetricValue
Price$140.25
Market Cap$2.01B
P/E Ratio-16.87
P/B Ratio55.66
P/S Ratio0.00
EPS (TTM)$-3.71
52-Week High$156.84
52-Week Low$20.35
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-34.25%
ROA-16.60%
ROCE-139.29%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.04
Current Ratio5.36

Annual Financials (USD)

Metric20212022202320242025
Revenue$31.0M$26.0M$0$0$0
Operating Profit$-52.0M$-43.0M$-12.0M$-14.0M$-39.0M
Net Profit$-46.0M$-33.0M$19.0M$-17.0M$-42.0M
EPS$-56.69$-29.61$14.74$-7.83$-3.71
Op Margin-165.0%-167.8%———

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$154.0M$17.0M$8.0M$88.0M$60.0M
Total Liabilities$103.0M$40.0M$11.0M$26.0M$32.0M
Cash$118.0M$16.0M$7.0M$84.0M$58.0M
Borrowings$15.0M$0$0$0$1.0M

Latest News

Palvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORIN Insider Monkey · Jul 15, 2026 Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors GlobeNewswire · Jun 30, 2026 Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations GlobeNewswire · Jun 29, 2026 What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally Motley Fool · Jun 27, 2026 Palvella Shares Advance After FDA Grants Rolling Review for Rare Disease Therapy InvestorsHub · Jun 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-8.0M$-15.0M$-14.0M$-11.0M$-25.0M
Investing Cash Flow$-2.0M$0$0$0$0
Financing Cash Flow$0$0$5.0M$9.0M$-1.0M
Net Cash Flow$47.0M$-5.0M$-9.0M$76.0M$-26.0M
Free Cash Flow$-9.0M$-15.0M$-14.0M$-11.0M$-25.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-1.95%
Quick Ratio28.88
Interest Coverage-6.50
Return 1Y272.94%
Return 3Y678.91%
Return 5Y-46.84%

Ownership

Insiders Held11.65%
Institutions Held97.04%
Institutions Float Held109.84%
Institutional HolderSharesReport Date
Suvretta Capital Management, LLC1,153,4962026-03-31
First Light Asset Management, LLC980,7582026-03-31
BVF Inc.960,9892026-03-31
Frazier Life Sciences Management, L.P. 882,4002026-03-31
Blackrock Inc.686,8532026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABUS $4.41 +0.00% -25.41 $871.14M 0.00%
EYPT $12.41 +1.80% -4.34 $1.04B 0.00%
GHRS $29.10 -0.06% -10.34 $2.00B 0.00%
KURA $9.57 +3.13% -2.90 $849.57M 0.00%
NBTXNanobiotix S.A. $40.18 +1.21% -68.71 $2.03B 0.00%

About PVLA

PVLA is led by CEO Wesley H. Kaupinen, employs 14 people, headquartered in US, publicly traded since 2015.

PVLA stock trades at $140.25 with a market capitalization of $2.01B. The stock is valued at a price-to-earnings (P/E) ratio of -16.87, price-to-book of 55.66, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $20.35 and $156.84, and currently trades 10.6% below its 52-week high.

On profitability, PVLA generates a return on equity (ROE) of -34.25%, return on capital employed of -139.29%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides